Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial carcinoma
• •Platinum-refractory or resistant disease
• •* At least 1 prior non-platinum chemotherapy agent required
• •Prior bilateral salpingo-oophorectomy and hysterectomy required
• •Bidimensionally measurable disease OR CA-125 greater than 100 units/mm3
• •PATIENT CHARACTERISTICS:
• •Age:
• •Over 18
• •Performance status:
• •Karnofsky 70-100%
• •Life expectancy:
• •More than 3 months
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •Bilirubin normal
• •AST no greater than 2.5 times upper limit of normal (ULN)
• •Renal:
• •Creatinine no greater than 1.5 times ULN OR
• •Creatinine clearance at least 50 mL/min
• •Other:
• •No other prior malignancy except non-melanoma skin cancer unless curatively treated with no evidence of disease within the past 5 years and at low risk for recurrence
• •No other clinical circumstances that would preclude study
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior biologic therapy and recovered
• •No prior thalidomide
• •Chemotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior cytotoxic therapy and recovered
• •Endocrine therapy:
• •At least 4 weeks since prior hormonal therapy and recovered
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy
• •Surgery:
• •See Disease Characteristics
• •At least 4 weeks since prior major surgery